BioRestorative Therapies Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Revenue Results. Additionally, the Company Reported Preliminary Phase 2 BRTX-100 Clinical Data Showing a Material Decrease in Pain and Increased...

BioRestorative Therapies股票交易上漲，因公司報告Q3營業收入超出預期。此外，公司報告初步2期BRTX-100臨床數據顯示疼痛明顯減少，並且...

Benzinga · 11/13 08:39

BioRestorative Therapies Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Revenue Results. Additionally, the Company Reported Preliminary Phase 2 BRTX-100 Clinical Data Showing a Material Decrease in Pain and Increased Function.

BioRestorative Therapies的股價在公司發佈超出預期的第三季度營業收入結果後上升。此外，該公司還發布了初步的第二階段BRTX-100臨床數據，顯示出疼痛顯著減輕和功能增加。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。